The new warning follows the FDA’s review of CMS studies and other data to assess Prolia patients’ risk of developing severe hypocalcemia, or very low blood calcium levels that can lead to hospitalization and death.
Severe hypocalcemia can cause “confusion, seizures, irregular heart rhythm, fainting, face twitching, uncontrolled muscle spasms [and] weakness,” the FDA said Jan. 19. The risk is highest among patients on dialysis.
Prolia (denosumab) is an monoclonal antibody first approved in 2010 for postmenopausal women with osteoporosis with a high risk for bone fracture. The FDA later added other approved indications for the medication that helps prevent cells from breaking down bones.
In a statement about the new boxed warning, the agency said healthcare professionals should assess patients’ kidney function and weigh the risk of severe hypocalcemia with Prolia against alternative treatments for osteoporosis.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.